decisionhealth Newsletters, Part B News - 2023 Issue 9 (September)
CMS unveils second list of negotiated Part B drug prices
Subscribe or sign in to view the full article.
Article Overview
This article covers CMS’s second announced list of Medicare Part B drugs affected by Inflation Reduction Act pricing changes, with emphasis on the timing of the update, the general impact on beneficiary coinsurance, and the broader context of Medicare drug pricing adjustments. It is relevant to professionals who track Medicare reimbursement policy, Part B drug pricing updates, and CMS implementation timelines for 2023.
Why This Topic Matters
The article helps readers monitor federal payment policy changes that can affect Medicare and Medicare Advantage beneficiary cost-sharing for Part B drugs, along with the operational timing of CMS price updates.
What You Will Learn
- How CMS is updating Medicare Part B drug pricing under the Inflation Reduction Act
- When the second list of Part B drug changes takes effect
- What categories of Medicare stakeholders are affected by the update
- How the announcement fits into the broader sequence of CMS drug pricing actions in 2023
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Compliance teams
- Healthcare administrators
- Pharmacy reimbursement specialists
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com